Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
Immunology
[키워드] accelerate
accelerated
acute respiratory distress
Adaptive immune response
adaptive immune system
anti-cancer response
approved
ARDS
Autoimmune
biological activity
Bone marrow
bone marrow failure
Cancer
Clinical data
clinical setting
clinical settings
COVID-19
database
Diseases
drug
Efficacy
ENhance
Essential
example
FDA
GM-CSF
granulocyte-macrophage colony-stimulating factor
hematologic
host immunity
humans
immune
Immune checkpoint inhibitor
immune modulation
Immune suppression
immune therapy
Immunotherapy
Infection
infections
innate immune response
less
modulating
monoclonal antibodies
objective
Other
Pulmonary alveolar proteinosis
reported
Result
resulting
review
safety profile
sargramostim
Sepsis
significantly
solid cancer
survival
syndrome
Therapies
therapy
tissue repair
Toxicity
trauma
US FDA
Vaccine
variety
[DOI] 10.3389/fimmu.2021.706186 PMC 바로가기 [Article Type] Immunology
[DOI] 10.3389/fimmu.2021.706186 PMC 바로가기 [Article Type] Immunology